Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment: Findings From the LIBERATE Study

ConclusionsApremilast demonstrated significant and sustained improvements in skin, scalp, nails, and PROs (pruritus and quality of life) over 104 weeks in patients with moderate to severe plaque psoriasis. Safety was consistent with the known safety profile of apremilast.This article is protected by copyright. All rights reserved.

Source: Journal of the European Academy of Dermatology and Venereology - December 8, 2017 Category: Dermatology Authors: K. Reich, M. Gooderham, A. Bewley, L. Green, J. Soung, R. Petric, J. Marcsisin, J. Cirulli, R. Chen, V. Piguet Tags: Short Report Source Type: research